Centhaquine
 | |
| Clinical data | |
|---|---|
| Trade names | Lyfaquin |
| Other names | Centhaquin; PMZ-2010; Compound-7173 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H25N3 |
| Molar mass | 331.463 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Centhaquine (brand name Lyfaquin) is a cardiovascular drug.[1] In India, it is approved for the treatment of hypovolemic shock.[2]
Centhaquine is a vasopressor that activates α2A- and α2B-adrenoreceptors.[3] It increases venous return and improves tissue perfusion.
References
[edit]- ^ Gulati A, Jain D, Agrawal NR, Rahate P, Choudhuri R, Das S, et al. (June 2021). "Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial". Advances in Therapy. 38 (6): 3223–3265. doi:10.1007/s12325-021-01760-4. PMC 8189997. PMID 33970455.
- ^ "Marketing authorization received for Lyfaquin (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency" (Press release). May 14, 2020. Archived from the original on August 9, 2022. Retrieved April 25, 2024.
- ^ Chalkias A, Pais G, Gulati A (March 2024). "Effect of Centhaquine on the Coagulation Cascade in Normal State and Uncontrolled Hemorrhage: A Multiphase Study Combining Ex Vivo and In Vivo Experiments in Different Species". International Journal of Molecular Sciences. 25 (6): 3494. doi:10.3390/ijms25063494. PMC 10970680. PMID 38542464.
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |